Semaglutide

910463-68-2

4113.64

DMSO : 33.33 mg/mL (ultrasonic)

GPCR/G Protein

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment. IC50 & Target: GLP-1 receptor^[1]. In Vitro: Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib⁸, Arg³⁴) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38+/-0.06 nM^[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1^[3]. In Vivo: The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs^[1]. Semaglutide improves 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to NN-2211 in most parameters^[2].